Reactivation of Protocol: NRG-GY006, A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.”

NRG-GY006 was reactivated in August 2017 with sufficient supply for the accrual of 10 patients on Arm 2. The protocol accrued 10 patients on Arm 2 and temporarily closed to accrual January 4, 2018 pending approval of amendment #2. The most recent submitted amendment (version date 11/29/2017) has been approved and the trial is reactivated effective January 10, 2018.


Amendment 2 documents will be available on the CTSU website within 24 hours.

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.